Health ❯ Healthcare

Cancer Statistics

Incidence Rates Survival Rates Breast Cancer Statistics Global Health Mortality Rates Bladder Cancer Statistics Prostate Cancer Incidence Diagnosis and Treatment UK Cancer Rates Bowel Cancer Statistics Breast Cancer Incidence Epidemiology Patient Prognosis Cancer Mortality Rates Misdiagnosis Early Detection Demographics Patient Outcomes Survivorship Research Colorectal Cancer Prostate Cancer Statistics Diagnosis Trends Liver Cancer Detection Rates Prostate Cancer Public Health Disease Prevalence Ovarian Cancer Incidence Bladder Cancer Incidence Risk Assessment Head and Neck Cancer Diagnosis Melanoma Statistics Regional Variations

Roche’s Giredestrant Cuts Early Breast Cancer Recurrence 30% in Phase III Trial

Regulatory filings are planned following the SABCS presentation with overall survival still immature.

FDA Clears Padcev Plus Keytruda Regimens as Perioperative Option for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

Final EMBARK Results Show 40% Lower Mortality With Enzalutamide Plus Leuprolide in High-Risk Recurrent Prostate Cancer

Lobular Breast Cancer Is Rising Fast, Now Over 1 in 10 U.S. Cases

AACR’s 2025 Report Shows Cancer Survival Gains as Early-Onset Cases Climb, Presses for Sustained U.S. Funding

Perioperative Immunotherapy and Liquid Biopsy Show Promise in Resectable Mesothelioma Phase 2 Trial

B7-H3 ADC Ifinatamab Deruxtecan Shows 48% Response in Relapsed ES-SCLC in Phase 2

Repurposed Drugs Clear Dormant Breast Cancer Cells in Phase II Trial

UChicago Medicine Launches First Cancer Network Affiliation With AdventHealth in Kansas City

Off-The-Shelf KRAS Vaccine Yields Robust T-Cell Responses and Survival Benefit

NICE Approves Keytruda Combo for Advanced Endometrial Cancer on NHS

Arvinas’ Vepdegestrant Delays Breast Cancer Progression Longer Than Faslodex